News
· 8hNovo Nordisk announces CEO transition as share price slips
After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts. Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight loss drugs.
A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...
The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...
The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.
Zepbound won on all measures of effectiveness in a trial presented Monday at an obesity conference, spurring an average of ...
Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
Everyday Health on MSN2d
Zepbound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
9hon MSN
In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback